Skip to Content


In the US, Capecitabine (capecitabine systemic) is a member of the drug class antimetabolites and is used to treat Breast Cancer, Breast Cancer - Metastatic, Colorectal Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cell Carcinoma and Stomach Cancer.

US matches:

UK matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Category

Cytostatic agent: Antimetabolite

Chemical Name

Carbamic acid, [1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl]-, pentyl ester

Foreign Names

  • Capecitabinum (Latin)
  • Capecitabin (German)
  • Capécitabine (French)
  • Capecitabina (Spanish)

Generic Names

  • Capecitabine (OS: BAN, USAN, JAN)
  • Capécitabine (OS: DCF)
  • Ro 09-1978/000 (IS: Roche)
  • Capecitabine (PH: Ph. Eur. 8, USP 38)

Brand Names

← International Drug Name Search


BANBritish Approved Name
DCFDénomination Commune Française
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
PHPharmacopoeia Name
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.